Robbins LLP Reminds REGN Stockholders of the Pending Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc.
Robbins LLP issued a reminder regarding the September 14, 2026 deadline to seek lead plaintiff appointment in a class action against Regeneron Pharmaceuticals. The lawsuit alleges that Regeneron misled investors concerning the viability and prospects of its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma, citing issues with statistical assumptions and clinical differentiation.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.